88results about How to "Efficient dosing" patented technology

The present invention relates to a shaped detergent composition, said composition comprising:

• • (a) a surfactant; and
  • (b) a plurality of discrete particles comprising benefit agent, said particles having a average particle size of at least 1.2 mm, preferably from 1.5 mm to 10 mm, more preferably from 2.0 mm to 5 mm, even more preferably from 2.3 mm to 4 mm.

The compositions of the present invention can be effectively dosed via the dispensing drawer of standard washing machines without being caught up in the mechanism of the.

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

The present invention generally provides taxane prodrugs comprising at least one taxane joined by hydrolyzable bond(s) to one or more polyethylene glycol oligomer(s) selected from the group consisting of a straight or branched polyethylene glycol oligomer having from 1 to 25 polyethylene glycol units and optionally comprising a salt-forming moiety. The polyethylene glycol oligomer preferably comprises a salt-forming moiety, which is preferably selected from the group consisting of ammonium and carboxylate.

A system and method for disinfecting hard surfaces in an area such as a hospital room including a light source emitting UV light and a reflector mounted behind the light source for concentrating and directing the light toward a target. The light source and reflector rotate to direct the concentrated beam around a room, thereby making more efficient use of the energy being emitted.

PCT No. PCT/EP96/05025 Sec. 371 Date May 26, 1998 Sec. 102(e) Date May 26, 1998 PCT Filed Nov. 12, 1996 PCT Pub. No. WO97/19601 PCT Pub. Date Jun. 5, 1997Fish oil concentrates, having: </=40% of long chain poly unsaturated fatty acids <20% of saturated fatty acids (C14-C18) <15% oleic acid <12% C16:1-fatty acid and with a weight-ratio: can be obtained by a process involving the following steps subjecting a fish oil to an enzymic conversion removing free fatty acids or esters from conversion-product subjecting product of above to enzymic hydrolysis, using specific lipase or partial glyceride-specific lipase wash and dry product re-esterify dried product.

The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.

A method of inhibiting angiogenesis in a mammal is disclosed, which employs a pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 (also known as casein kinase II) enzymatic activity, such as emodin, aloe-emodin, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), and 4,5,6,7-tetrabromobenzotriazole (TBB). Also disclosed is a use of a selective inhibitor of protein kinase CK2 enzymatic activity in the manufacture of a medicament for inhibiting angiogenesis. An in vitro method of screening a potential antiangiogenic agent is also disclosed. A kit for the treatment of a disease by inhibiting angiogenesis is disclosed that contains the pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 enzymatic activity.

Disclosed herein are compounds of the formula

wherein R₁ is independently H or alkyl of 1 to 6 carbons;

• R₂ is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF₃, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
• n is an integer of between 0 and 2;
• o is an integer between 0 and 3;
• R₃ is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I;
• R₄ is heteroaryl or (R₅)_p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N;
• p is an integer having the values of 0–5;
• R₅ is F, Cl, Br, I, NO₂, N(R₈)₂, N(R₈)CORO₈, N(R₈)CON(R₈)₂, OH, OCOR₈, OR₈, CN, COOH, COOR₈, C_1-10 alkyl, fluoro substituted C_1-10 alkyl, C_2-10 alkenyl having 1 to 3 double bonds, C_2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons;
• A is (CH₂)_q where q is 0–5, C_3-6 branched alkyl, C_3-6 cycloalkyl, C_2-6 alkenyl having 1 or 2 double bonds, or C_2-6 alkynyl having 1 or 2 triple bonds;
• B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COORO₈, CONR₉R₁₀, CH₂OH, CH₂OR₁₁, CH₂OCOR₁₁, CHO, CH(OR₁₂)₂, CHOR₁₃O, COR₇, CR₇(OR₁₂)₂, CR₇OR₁₃O, or Si(C_1-6alkyl)3;
• R₇ is C_1-5 alkyl, C_3-5 cycloalkyl, or C_2-5 alkenyl;
• R₈ is C_1-10 alkyl, C_1-10 (trimethylsilyl)alkyl, or C_5-10 cycloalkyl;
• R₉ and R₁₀ are independently hydrogen, C_1-10 alkyl, C_5-10 cycloalkyl, phenyl or R₁₂-phenyl;
• R₁₁ is C_1-6 alkyl, phenyl, or R₁₂-phenyl;
• R₁₂ is C_1-6 alkyl; and
• R₁₃ is divalent alkyl radical of 2–5 carbons.

The invention relates to the fact that a common industrial neutron interrogation screening requirement is that a high throughput rate be accommodated by the screening system. The accumulation of elemental abundance ratio spectral data to minimize statistical uncertainty is a function of the neutron flux passing through the subject. If the subject passes through a neutron beam, with a strictly limited time window for exposure, the flux must be sufficient to accumulate the required statistics. The level of neutron flux necessary may exceed the cost effective limits of the selected neutron source means. Exposure time window dilation is disclosed through a class of system configurations which become practical for reduction to practice by utilization of linear neutron source topology neutron generators. This disclosure is concerned with example embodiments which utilize the length, width, thickness and segmentation of the source emission zone within an appropriate neutron source.

A medicine ejection device is provided allowing a medicine with a desired droplet diameter to be inhaled at a constant rate. The medicine ejection device has a decision part at which the ejection operating conditions of a medicine ejection part for ejecting the medicine are decided in accordance with at least one of an open-air environment or a state of the medicine during use of the device. The device ejects the medicine according to the ejection operating conditions decided by the decision part.

The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.

The invention relates to the technical field of agriculture, in particular to a pesticide spraying device and method, and particularly discloses an automatic and accurate pesticide feeding device and method for an agricultural UAV. The automatic and accurate pesticide feeding device for the agricultural UAV is characterized in that a first lifting unit is mounted on a trolley; a pesticide conveying box is arranged on the trolley, connected with the UAV and used for feeding pesticide to the UAV; a second lifting unit is connected with the first lifting unit, and a weighing unit is arranged on the second lifting unit; and a controller is used for controlling ascending and descending of the first lifting unit and the second lifting unit, receiving a signal of the weighing unit and controlling the pesticide conveying box to feed the pesticide to the UAV. According to the automatic and accurate pesticide feeding device, the accurate controlling of UAV dosage is achieved, the maximum take-off load is not exceeded when the pesticide is fed to the UAV, or fast and accurate feeding is realized according to a dosage requirement of accurate pesticide application, and the work efficiency of the UAV is improved; and further, the device can perform mobile operation, so that the problem that the carrying is inconvenient when the pesticide is fed to the UAV is solved.

An automatic injector separately stores liquid and dry components in respective compartments. When the injector is activated, a fluid-directing member between the liquid and dry compartments causes the liquid component to form a vortex as the liquid flows into the dry compartment. This allows the two components to combine more thoroughly and quickly to form a liquid solution that is delivered to an injection site.

The invention relates to new compositions comprising an aldosterone antagonist according to a particular posology for the treatment of heart failure in non-human mammal animals.